The molecular mechanisms and therapeutic strategies of EMT in tumor progression and metastasis
Y Huang, W Hong, X Wei - Journal of hematology & oncology, 2022 - Springer
Epithelial–mesenchymal transition (EMT) is an essential process in normal embryonic
development and tissue regeneration. However, aberrant reactivation of EMT is associated …
development and tissue regeneration. However, aberrant reactivation of EMT is associated …
Circulating tumor cell isolation for cancer diagnosis and prognosis
Circulating tumor cells (CTCs) are tumor cells that shed from the primary tumor and
intravasate into the peripheral blood circulation system responsible for metastasis. Sensitive …
intravasate into the peripheral blood circulation system responsible for metastasis. Sensitive …
Cancer evolution: Darwin and beyond
Clinical and laboratory studies over recent decades have established branched evolution as
a feature of cancer. However, while grounded in somatic selection, several lines of evidence …
a feature of cancer. However, while grounded in somatic selection, several lines of evidence …
Olaparib in patients with metastatic castration-resistant prostate cancer with DNA repair gene aberrations (TOPARP-B): a multicentre, open-label, randomised, phase …
Background Metastatic castration-resistant prostate cancer is enriched in DNA damage
response (DDR) gene aberrations. The TOPARP-B trial aims to prospectively validate the …
response (DDR) gene aberrations. The TOPARP-B trial aims to prospectively validate the …
Genetics and biology of prostate cancer
Despite the high long-term survival in localized prostate cancer, metastatic prostate cancer
remains largely incurable even after intensive multimodal therapy. The lethality of advanced …
remains largely incurable even after intensive multimodal therapy. The lethality of advanced …
Metastatic prostate cancer
O Sartor, JS de Bono - New England Journal of Medicine, 2018 - Mass Medical Soc
Metastatic Prostate Cancer Interventions added to androgen-deprivation therapy in men with
metastatic prostate cancer have recently been noted to increase survival. Decisions about …
metastatic prostate cancer have recently been noted to increase survival. Decisions about …
Circulating tumor DNA genomics correlate with resistance to abiraterone and enzalutamide in prostate cancer
Primary resistance to androgen receptor (AR)–directed therapies in metastatic castration-
resistant prostate cancer (mCRPC) is poorly understood. We randomized 202 patients with …
resistant prostate cancer (mCRPC) is poorly understood. We randomized 202 patients with …
Trial design and objectives for castration-resistant prostate cancer: updated recommendations from the Prostate Cancer Clinical Trials Working Group 3
HI Scher, MJ Morris, WM Stadler, C Higano… - Journal of Clinical …, 2016 - ascopubs.org
Purpose Evolving treatments, disease phenotypes, and biology, together with a changing
drug development environment, have created the need to revise castration-resistant prostate …
drug development environment, have created the need to revise castration-resistant prostate …
DNA-repair defects and olaparib in metastatic prostate cancer
Background Prostate cancer is a heterogeneous disease, but current treatments are not
based on molecular stratification. We hypothesized that metastatic, castration-resistant …
based on molecular stratification. We hypothesized that metastatic, castration-resistant …
Clinical applications of circulating tumor cells and circulating tumor DNA as liquid biopsy
C Alix-Panabières, K Pantel - Cancer discovery, 2016 - AACR
Abstract “Liquid biopsy” focusing on the analysis of circulating tumor cells (CTC) and
circulating cell-free tumor DNA (ctDNA) in the blood of patients with cancer has received …
circulating cell-free tumor DNA (ctDNA) in the blood of patients with cancer has received …